Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy
Table 4
Immunolocalization of EGF ligand using 2 different monoclonal antibodies.
H-score
Histopathological type
0
1
2
No. (%)
No. (%)
No. (%)
SCLC
CB-EGF1
2/12 (16.67)
6/12 (50.0)
4/12 (33.33)
CB-EGF2
5/12 (41.67)
5/12 (41.67)
2/12 (16.67)
NSCLC
Squamous cell carcinoma
CB-EGF1
3/20 (15.00)
12/20 (60.00)
5/20 (25.00)
CB-EGF2
6/20 (30.00)
13/20 (65.00)
1/20 (5.00)
Adenocarcinoma
CB-EGF1
5/23 (21.74)
9/23 (39.13)
9/23 (39.13)
CB-EGF2
8/23 (34.78)
10/23 (43.48)
5/23 (21.74)
Large cell carcinoma
CB-EGF1
1/6 (16.67)
2/6 (33.33)
3/6 (50.00)
CB-EGF2
0/6 (00.00)
3/6 (50.00)
3/6 (50.00)
Other
CB-EGF1
3/10 (30.00)
1/10 (10.00)
6/10 (60.00)
CB-EGF2
4/10 (40.00)
3/10 (30.00)
3/10 (30.00)
SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; No.: number of cases; %: percentages; 0: negative; 1: scores ; 2: scores .
